Unknown

Dataset Information

0

Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.


ABSTRACT: Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on markers of these pathways in patients with type 2 diabetes and nephropathy.Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n?=?39) or placebo (n?=?43). Plasma and urinary AGEs (N(?)-(carboxymethyl) lysine [CML], N(?)-(Carboxyethyl) lysine [CEL], and 5-hydro-5-methylimidazolone [MG-H1]) and plasma markers of endothelial dysfunction (soluble vascular cell adhesion molecule-1 [sVCAM-1], soluble intercellular adhesion molecule-1 [sICAM-1], soluble E-selectin) and low-grade inflammation (high-sensitivity C-reactive protein [hs-CRP], serum amyloid-A [SAA], myeloperoxidase [MPO]) were measured at baseline and after 6 and 12 weeks.Compared to placebo, benfotiamine did not result in significant reductions in plasma or urinary AGEs or plasma markers of endothelial dysfunction and low-grade inflammation.Benfotiamine for 12 weeks did not significantly affect intermediate pathways of hyperglycemia-induced vascular complications. TRIAL REGRISTRATION: ClinicalTrials.gov NCT00565318.

SUBMITTER: Alkhalaf A 

PROVIDER: S-EPMC3391239 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy.

Alkhalaf Alaa A   Kleefstra Nanne N   Groenier Klaas H KH   Bilo Henk J G HJ   Gans Reinold O B RO   Heeringa Peter P   Scheijen Jean L JL   Schalkwijk Casper G CG   Navis Gerjan J GJ   Bakker Stephan J L SJ  

PloS one 20120706 7


<h4>Background</h4>Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on markers of these pathways in patients with type 2 diabetes and nephropathy.<h4>Methods</h4>Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15-300 mg/24h) were randomized to receive benfotiamine (n   ...[more]

Similar Datasets

| S-EPMC6676393 | biostudies-literature
| S-EPMC5700925 | biostudies-literature
| S-EPMC9820473 | biostudies-literature
| S-EPMC6491451 | biostudies-literature
| S-EPMC5101164 | biostudies-literature
| S-EPMC8192873 | biostudies-literature
| S-EPMC5817812 | biostudies-other
| S-EPMC5237628 | biostudies-literature
| S-EPMC7521722 | biostudies-literature
| S-EPMC6692010 | biostudies-literature